Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on Dec 12, 2023 12:05pm
266 Views
Post# 35780085

Exec compensation

Exec compensationDecember is a month that MC and his team will often issue themselves a boatload of options as reward for their wonderful work during the year.

Shareholders have reason to be upset if this egregious behavior happens now.

2023 has been an awful year for ONC. The board and MC have nothing to be celebrating. They have done nothing to increase share price. In fact, MC's dealings with Anson demonstrate complete incompetence and prove that he has no concern at all for ONC's shareholders. Simply, he wants to protect his own annual wages and continue to play minecraft or whatever the hell he does at work all day while he waits for some miraculous call from big pharma.

Crunch time tomorrow for MC. Will he pony up some cash (175000*$1.45) and at last hold some decent amount of shares or will he sell his converted shares and take the money and run and snub his nose at shareholders?
<< Previous
Bullboard Posts
Next >>